MITIGAAT: Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants

Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Aug 29, 2023

Keywords

ClinConnect Summary

The MITIGAAT trial is a study designed to help improve the health and outcomes of kidney transplant patients, especially focusing on African American patients. Researchers are testing a smartphone app that will be used by a pharmacist to assist patients in tracking their medications, blood pressure, and blood sugar levels if they have diabetes. By using this app, the goal is to ensure that patients stick to their medication plans and monitor their health more effectively.

To participate in this study, you need to be at least 18 years old and have had a kidney transplant for two or more years. Unfortunately, if you received a different type of transplant (like a liver or heart transplant) or if you have difficulty measuring your blood pressure or blood sugar, you would not be eligible. Participants will receive training on how to use the app, and the study is currently looking for volunteers. This trial aims to make a positive difference in the care of kidney transplant patients and help them achieve better health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years of age
• • ≥2 years post-kidney transplant
• Exclusion Criteria:
• • Non-kidney transplant recipient (liver, lung, heart, intestine, pancreas, bone marrow)
• • Not capable of measuring own BP and glucose in those with diabetes
• • Not capable of using mobile health application after adequate training
• • Not capable of speaking, hearing, and reading English